Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROPER: Pain Relief at Screening for Retinopathy of Prematurity
2023-507975-23-01Phase 2Authorised
- Sponsor
- St. Olavs University Hospital
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised trial of dexmedetomidine in retinopathy of prematurity (ROP) (2 arms), sponsored by St. Olavs University Hospital. Primary endpoint: Pain score during 30 seconds after speculum insertion. Planned start Jun 2026; status: authorised.
02
Drugs
dexmedetomidine
03
Conditions
retinopathy of prematurity (ROP)
Beyond the preview
Go deeper on 2023-507975-23-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507975-23-01.